title: Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
abstract: Clinical trials have demonstrated the efficacy of cholinesterase inhibitors (ChEI) in improving cognitive status and disability in subjects with mild to moderate Alzheimer's disease (AD). However, little is known about the effectiveness of ChEI in clinical practice, and no large clinical trials comparing different ChEI are available at present. Aim of this study was to evaluate safety and effectiveness of ChEI in a sample of elderly outpatients diagnosed with mild to moderate AD. We selected 407 subjects for ChEI treatment (donepezil,rivastigmine or galantamine). Their cognitive function was evaluated by means of the mini mental state examination (MMSE), and the global functional status was estimated by using the activities of daily living (ADL) and the instrumental activities of daily living (IADL) scales at baseline (To), then after 1 (T1), 3 (T2) and 9 months (T3), respectively. T3 follow-up was completed by 212 subjects. The patients were considered as responders (R), if the MMSEscore at T2 was unchanged or improved, if compared to that of T0. In 35 patients (8.6 %)treatment was withdrawn because of mostly gastrointestinal adverse events. Compared to the other drugs, donepezil was associated with a lower incidence of withdrawals due to adverse events. Subjects who completed T3 follow-up (age 78 +/- 6 years, MMSE scores 18.8 +/- 3.9) showed an increase at T2 of 0.7 +/- 2.7 (p = 0.001) and a decrease at T3 of -0.6 +/- 3.4 (p = 0.008) in the MMSE scores, as compared to To . The ADL and IADL scores did not show significant changes at T2; however, both decreased significantly at T3. The patients Rat-T2 showed a better cognitive and functional outcome at T3 , compared to the nonresponders(NR-at-T2), displaying values of MMSE R-at-T2 0.4 +/- 3.1 vs. NR-at-T2 -3.0 +/- 2.5, p = 0.001, and ADL values of -0.3 +/- 1.2 vs. -0.7 +/- 1.3, p = 0.03, respectively. No significant difference was found in the changes of MMSE scores between donepezil and rivastigmine (galantamine was not included in the comparison due to the small number of treated subjects). In conclusion, in this sample of elderly subjects with mild to moderate AD,treated with ChEI, a small but significant decline in cognitive and functional status was observed after 9 months. Subjects who showed a good response to treatment after 3 months, had a better cognitive and functional outcome at 9 months. No significant difference in cognitive outcome was found between drugs, while donepezil was better tolerated.
authors.affiliation: Department of Critical Care Medicine and Surgery, Unit of Gerontology and Geriatric Medicine, University of Florence, A.O. Careggi, I-50141 Firenze, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Mossello
authors.forename: E
authors.initials: E
authors.lastname: Tonon
authors.forename: V
authors.initials: V
authors.lastname: Caleri
authors.forename: S
authors.initials: S
authors.lastname: Tilli
authors.forename: C
authors.initials: C
authors.lastname: Cantini
authors.forename: M C
authors.initials: MC
authors.lastname: Cavallini
authors.forename: F
authors.initials: F
authors.lastname: Bencini
authors.forename: R
authors.initials: R
authors.lastname: Mecacci
authors.forename: M
authors.initials: M
authors.lastname: Marini
authors.forename: F
authors.initials: F
authors.lastname: Bardelli
authors.forename: E
authors.initials: E
authors.lastname: Sarcone
authors.forename: E
authors.initials: E
authors.lastname: Razzi
authors.forename: C A
authors.initials: CA
authors.lastname: Biagini
authors.forename: G
authors.initials: G
authors.lastname: Masotti
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy*; D002219:Carbamates / Q000009:adverse effects; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy; D000077265:Donepezil; D005260:Female; D005702:Galantamine / Q000009:adverse effects; D006801:Humans; D007189:Indans / Q000009:adverse effects; D008297:Male; D009483:Neuropsychological Tests; D048448:Phenylcarbamates; D010880:Piperidines / Q000009:adverse effects; D000068836:Rivastigmine; D012720:Severity of Illness Index
chemical_list: D002219:Carbamates; D002800:Cholinesterase Inhibitors; D007189:Indans; D048448:Phenylcarbamates; D010880:Piperidines; D005702:Galantamine; D000077265:Donepezil; D000068836:Rivastigmine